Novartis Future Growth
Future criteria checks 2/6
Novartis is forecast to grow earnings and revenue by 7% and 2.2% per annum respectively. EPS is expected to grow by 9.2% per annum. Return on equity is forecast to be 37% in 3 years.
Key information
7.0%
Earnings growth rate
9.2%
EPS growth rate
Pharmaceuticals earnings growth | 11.9% |
Revenue growth rate | 2.2% |
Future return on equity | 37.0% |
Analyst coverage | Good |
Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative
Nov 05Investors Interested In Novartis AG's (VTX:NOVN) Earnings
Oct 21Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet
Sep 04Novartis AG's (VTX:NOVN) Price In Tune With Earnings
Mar 12Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30
Feb 20Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?
Jan 04Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 53,242 | 13,195 | 16,857 | 19,530 | 14 |
12/31/2025 | 52,663 | 12,472 | 16,067 | 18,507 | 17 |
12/31/2024 | 50,479 | 10,989 | 14,775 | 16,979 | 15 |
9/30/2024 | 49,940 | 11,761 | 12,552 | 15,973 | N/A |
6/30/2024 | 48,860 | 10,083 | 13,560 | 15,065 | N/A |
3/31/2024 | 47,733 | 9,107 | 12,071 | 13,766 | N/A |
12/31/2023 | 46,660 | 8,568 | 13,660 | 14,458 | N/A |
9/30/2023 | 45,850 | 7,245 | 15,507 | 16,022 | N/A |
6/30/2023 | 44,541 | 7,062 | 13,241 | 15,365 | N/A |
3/31/2023 | 41,694 | 5,976 | 14,009 | 15,544 | N/A |
12/31/2022 | 43,461 | 6,049 | 12,167 | 14,236 | N/A |
9/30/2022 | 46,017 | 21,042 | 11,545 | 14,009 | N/A |
6/30/2022 | 48,601 | 22,472 | 11,714 | 14,213 | N/A |
3/31/2022 | 52,997 | 24,184 | 12,349 | 14,590 | N/A |
12/31/2021 | 43,974 | 22,908 | 13,201 | 15,071 | N/A |
9/30/2021 | 52,385 | 9,807 | 13,015 | 15,192 | N/A |
6/30/2021 | 51,556 | 8,984 | 11,222 | 13,423 | N/A |
3/31/2021 | 49,884 | 7,955 | 10,699 | 13,252 | N/A |
12/31/2020 | 49,898 | 8,072 | 11,445 | 13,650 | N/A |
9/30/2020 | 49,584 | 7,103 | 11,743 | 13,185 | N/A |
6/30/2020 | 49,528 | 7,210 | 13,255 | 14,591 | N/A |
3/31/2020 | 49,930 | 7,451 | 13,077 | 14,240 | N/A |
12/31/2019 | 48,677 | 7,142 | 12,341 | 13,625 | N/A |
9/30/2019 | 47,858 | 7,238 | 12,122 | 13,851 | N/A |
6/30/2019 | 46,762 | 7,077 | 11,477 | 13,339 | N/A |
3/31/2019 | 46,391 | 12,697 | 11,778 | 13,671 | N/A |
12/31/2018 | 46,099 | 12,797 | 12,447 | 14,272 | N/A |
9/30/2018 | 47,366 | 13,552 | 11,748 | 13,914 | N/A |
6/30/2018 | 48,672 | 13,752 | N/A | 13,450 | N/A |
3/31/2018 | 49,513 | 8,004 | N/A | 13,090 | N/A |
12/31/2017 | 43,404 | 7,499 | N/A | 12,621 | N/A |
9/30/2017 | 49,527 | 6,684 | N/A | 12,804 | N/A |
6/30/2017 | 49,176 | 6,543 | N/A | 12,449 | N/A |
3/31/2017 | 49,361 | 6,367 | N/A | 11,978 | N/A |
12/31/2016 | 49,386 | 6,712 | N/A | 11,475 | N/A |
9/30/2016 | 49,606 | 6,807 | N/A | 12,041 | N/A |
6/30/2016 | 49,750 | 6,672 | N/A | 11,936 | N/A |
3/31/2016 | 49,967 | 6,722 | N/A | 11,735 | N/A |
12/31/2015 | 50,387 | 7,017 | N/A | 11,897 | N/A |
9/30/2015 | 50,635 | 8,417 | N/A | 12,945 | N/A |
6/30/2015 | 51,450 | 9,697 | N/A | 13,830 | N/A |
3/31/2015 | 52,503 | 10,536 | N/A | 14,260 | N/A |
12/31/2014 | 53,634 | 10,657 | N/A | 13,897 | N/A |
9/30/2014 | 53,908 | 10,191 | N/A | 13,142 | N/A |
6/30/2014 | 53,514 | 9,233 | N/A | 13,510 | N/A |
3/31/2014 | 52,845 | 9,095 | N/A | 12,687 | N/A |
12/31/2013 | 52,716 | 9,192 | N/A | 13,174 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NOVN's forecast earnings growth (7% per year) is above the savings rate (0.3%).
Earnings vs Market: NOVN's earnings (7% per year) are forecast to grow slower than the Swiss market (11% per year).
High Growth Earnings: NOVN's earnings are forecast to grow, but not significantly.
Revenue vs Market: NOVN's revenue (2.2% per year) is forecast to grow slower than the Swiss market (4.3% per year).
High Growth Revenue: NOVN's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NOVN's Return on Equity is forecast to be high in 3 years time (37%)